Day: September 20, 2021

Posted on

کامیابی سے منعقد ہونے والی17 ویں سی آئی ایس ایم ای ایف کا مقصد دنیا بھر میں ایس ایم ایز کو فوائد اور مواقع فراہم کرنا تھا

گوانگژو، چین 20ستمبر 2021 /ژن ہوا-ایشیا نیٹ / –17ویں چائنا انٹرنیشنل  اسمال اینڈ میڈیم انٹرپرائز کا میلہ (سی ایس ایم ای ایف)16ستمبر تا 19ستمبر تک جنوبی چین کے صوبہ گوانگڈانگ کے دارالحکومت گوانگژو میں منعقد ہوا۔اس میلے نے 30سے زائد ممالک اور خطوں سے کمپنیوں کو شرکت کے لیے اپنی جانب متوجہ کیا۔یہ ایک زبردست پلیٹ فارم ہےاور ایس ایم ایز کو اندرون ملک اور بیرون ملک میں تعاون اور ترقی کا معیار بڑھانے کے نئے مواقع فراہم کرتاہے۔

روبوٹک ہاتھ ،خودکار گائیڈڈ گاڑیاں،مختلف مصنوعات نظروں کو دعوت دیتی ہے۔

تقریباً 1000کمپنیاں، جو یا تو مخصوص ٹیکنالوجی  میں سبقت رکھتی ہے،یا   ریفائنڈ مصنوعات اور تکنیک،نایاب اشیائ  یا سہولیات،یا ٹیکنالوجی اوریا پیداواری طریقے میں اختراعات،کرنے والی کمپنیوں نے سی آئی ایس ایم ای ایف میں حصہ لیا۔انھوں نے زیادہ تر بہترین تیاری اور مصنوعی ذہانت ،سازوسامان کی تیاری،الیکٹرانک معلومات ،بائیو میڈیسن،اور غذا اور زراعت جیسی صنعتی شعبوں پر توجہ دی ۔

شاندار نمائشوں کے علاوہ،کاروبار کےترقی کے مواقع اور سرگرمیوں کے تبادلے کی تمام اقسام بھی قابل توجہ ہیں۔سی آئی ایس ایم ای ایف نے سرگرمیوں کے ایک سلسلے کا بندوبست کیا جس کا ہدف نمائشی صنعتی شعبے ہیں،جن میں 12سپلائی اور ڈیما نڈ  کی ڈاکنگ سرگرمیاں،4موضوعاتی سرگرمیاں،3سرحد پار کاروباری معاہدے طے کرانے کی سرگرمیاں اور بیرون ملک نمائش کنندگان کے لیے 6تشہیری سرگرمیاں،اس امید کے ساتھ کہ نمائش کنندگان اور خریدار وں کو مزید جامع اور پر اثر سہولیات فراہم کیں جائے۔

گوانگژو کی کیمسون ٹریڈ کمپنی لمیٹیڈ پہلی بار سی آئی ایس ایم ای ایف میں حصہ لے رہی ہے۔کیمسون الیکٹرواسٹیٹک پاوٗڈر کوٹنگ ایریا میں مہارت رکھتی ہے،اور اپنے صارفین کو ذہین خودکار کوٹنگ اسکیم اور سہولیات فراہم کرتی ہے۔کیمسون کے ریسرچ اور ڈیولپمنٹ ڈائریکٹر شو گن کا کہناتھا ’’سی آئی ایس ایم ای ایف ہمارے جیسی خاص ٹیکنالوجی والی کمپنیوں کو ایک زبردست پلیٹ فارم مہیا کرتا ہے۔ایک طرف،ہمارے پاس موقع ہے کہ ہم اپنی مصنوعات اور برانڈ کی تشہیر کریں۔اور دوسر ی طرف، یہ ہمیں دوسرے شعبوں سے منفرد ٹیکنالوجی کے بارے میں سیکھنے میں مدد کرتاہے،جو پھر ہم یاد کر کے اپنے شعبے میں استعمال کرتے ہیں،اور صارفین کو بہتر سہولیات فراہم کرتے ہیں۔‘‘

رونمائی،لین دین،تبادلہ،تعاون۔سی آئی ایس ایم ای ایف ایک ایسے اہم پلیٹ فارم کے طور پر کام کرتا ہے جو دنیا بھر کے ایس ایم ایز کے لیے بنایاگیاہے۔یہ کمپنیوں کو سپلائر اور خریدار کے مابین تعاون کے لیے معلومات اور کاروباری ،اور تکنیکی تبادلے کے مواقع فراہم کرتاہے۔اسی دوران،یہ نمائش چین کے ابلاغ کے فروغ کی اور اندرون و بیرون ملک ایس ایم ایز کے مابین تعاون کی جانب زبردست راہ دکھاتاہے،اور کثیر الجہتی تجارت کا مشورہ دیتاہے۔

ایس ایم ایز کے لیے بین الاقوامی تعاون سمٹ،نمائش کے ساتھ مل کر،عالمی سطح پر ایس ایم ایز کے حصول کےقابل غورایک  منصوبے کاباقاعدہ اعلان کیا،جس کی مالیت 826.3بلین یوآن ہے۔سیمیناروں کا ایک سلسلہ رکھا گیا،جن میں ایس ایم ای کی حکمت عملیوں پر وزیروں کی سطح پر ایک راوٗ نڈ ٹیبل سیمینار تھا،جس میں ان تجربات کا تبادلہ کیاگیا کہ کس طرح ایس ایم ایز کی مشکلات کو بہتر طریقے سے حل کیاجائے۔

کئی نمائش کنندگان کے لیے،ایس ایم ایز کی یہ زبردست بین الاقوامی تقریب ان کو عالمی کاروباری سرگرمیوں کے ساتھ جڑنے کو مزید بڑھائیں گی اور باہمی فوائد اور عام ترقی حاصل کرنے میں مدد کرے گی۔گوانگڈانگ جیٹن روبوٹ اینڈ آٹومیشن کمپنی لمیٹیڈ نے اس میلے میں نئی خودکار گائیڈڈ  گاڑیاں پہلی بار متعارف کرائیں۔کمپنی کے ڈپٹی جنرل منیجر وانگ میکوئی کا خیال ہے کہ سی آئی ایس ایم ای ایف مصنوعات کی تشہیر کے لیے ایک اچھا موقع فراہم کرتاہے۔ان کا کہناتھا’’ہم چاہتے ہیں کہ مزیدلوگ ہماری مصنوعات کے بارے میں جانیں، اور یہ بہت اہم ہے۔‘‘

ذریعہ : سی آئی ایس ایم ای ایف

Posted on

Adagio Therapeutics Provides COVID-19 Antibody Program Updates as well as Business Highlights and Second Quarter 2021 Financial Results

New Data Supporting Potential of ADG20 for Both the Treatment and Prevention of COVID-19 to be Presented at IDWeek 2021

Patient Population in Global EVADE Phase 2/3 Clinical Trial of ADG20 Expanded following IDMC Assessment

$355.8 Million IPO Completed to Fund Continued Advancement of Portfolio of Antibody-based Solutions for Infectious Diseases with Pandemic Potential

WALTHAM, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today reported updates on its lead COVID-19 antibody program, ADG20, as well as recent business highlights and second quarter 2021 financial results.

“Across the globe, COVID-19 continues to be a significant health crisis affecting nearly every age group. With the continued emergence of new variants, broadly neutralizing therapies that can be used for both the treatment and prevention of the disease are critical to address the current endemic as well as potential future outbreaks,” said Tillman Gerngross, Ph.D., co-founder and chief executive officer of Adagio. “Our team is working closely with our global CRO partners on the execution of our ongoing global clinical trials of ADG20, STAMP and EVADE, while also preparing for the anticipated worldwide commercialization of ADG20, if approved.

“ADG20 is a highly differentiated antibody that we are advancing through pivotal trials for both the treatment and prevention of COVID-19. We are pleased by the recent assessment of unblinded data by the IDMC for the EVADE trial, and their support of our plans to expand enrollment to include adolescents and pregnant or nursing women,” said Lynn Connolly, M.D., Ph.D., chief medical officer of Adagio. “To date, we have generated a compelling data package for ADG20 that includes broad neutralization of the original SARS-CoV-2 virus and the known variants of concerns in in vitro models as well as a favorable pharmacokinetic and tolerability profile in our Phase 1 trial. Further, at this year’s IDWeek, we will release additional data from our Phase 1 trial as well as details regarding our dose selection process for treatment and prevention, which we believe further support the important role this novel antibody can play in combatting the ongoing pandemic.”

ADG20 COVID-19 Program Highlights

  • New ADG20 Data to be Presented in Multiple Posters during IDWeek: At the IDWeek 2021 Virtual Conference, Adagio plans to present additional data highlighting the potential for ADG20 to provide protection from COVID-19 for up to one year based on its extended half-life in humans combined with its broad and potent neutralizing ability demonstrated in laboratory testing. In addition, the data support the evaluation of a 300mg dose, delivered as a single intramuscular injection, in the ongoing Phase 2/3 STAMP (treatment) and EVADE (prevention) global clinical trials. The data will be presented in multiple posters, which will be available to registered attendees on the virtual platform throughout the duration of the conference, being held from September 29 – October 3, 2021. The presentations include:
    • 1086: A Whole-Body Quantitative System Pharmacology Physicologically-Based Pharmacokinetic (QSP/PBPK) Model that a priori Predicts Intramuscular (IM) Pharmacokinetics of ADG20: an Extended Half-life Monoclonal Antibody Being Developed for the Treatment and Prevention of Coronavirus Disease (COVID-19)
    • 633: Preliminary Results from a Phase 1 Single Ascending-Dose Study Assessing Safety, Serum Viral Neutralizing Antibody Titers (sVNA), and Pharmacokinetic (PK) Profile of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment and Prevention of Coronavirus Disease (COVID-19)
    • 1089: Use of a Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Prevention of Coronavirus Disease (COVID-19)
    • 1088: A Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment of Coronavirus Disease (COVID-19)
  • Patient Population Expanded in EVADE following IDMC Data Assessment: The independent data monitoring committee (IDMC) for the EVADE Phase 2/3 trial of ADG20 for the prevention of COVID-19 recently provided a recommendation to expand Phase 3 trial enrollment to include adolescents 12 years and older and pregnant or nursing women, as well as a decrease in the protocol-specified, in-clinic post injection monitoring time. The IDMC’s recommendations were based on their review of unblinded safety and tolerability data through the Day 28 post-treatment visit from 200 participants enrolled in the Phase 2 lead-in portion of the trial.
  • Partnership with Biocon Biologics Expands the Reach of a Potent and Broadly Neutralizing COVID-19 Antibody Treatment to Patients in India and Select Emerging Markets: In the second quarter of 2021, Adagio partnered with Biocon Biologics Ltd. to combat the ongoing COVID-19 crisis in southern Asia. The partnership provides Biocon rights to manufacture and commercialize an antibody therapy based on ADG20 in India and additional select emerging markets based on the commercial manufacturing process developed for ADG20. As part of the agreement, Biocon will be granted access to data from Adagio’s Phase 2/3 clinical trials as well as its anticipated Emergency Use Authorization package and other regulatory submissions to support approval or emergency authorization in India and other select emerging markets.

Recent Business Highlights

  • David Hering, Global COVID-19 Vaccine Expert, Appointed as Chief Operating Officer: Adagio recently appointed David Hering as the company’s chief operating officer. Mr. Hering joins Adagio from Pfizer, where he most recently served as the global mRNA business lead, a business specifically created to manage global COVID-19 efforts as well as future vaccines utilizing mRNA technology, and led the launch of the first-ever COVID-19 vaccine in the United States. Prior to his most recent role at Pfizer, Mr. Hering was president, North America at Pfizer, where he led a 700-person organization across a portfolio of vaccine products for COVID-19 and meningococcal and pneumococcal diseases.
  • $355.8 Million Initial Public Offering (IPO) Successfully Completed: In August 2021, Adagio sold 20,930,000 shares of common stock, including the full exercise of the underwriters’ option to purchase an additional 2,730,000 shares of common stock at a public offering price of $17.00 per share. The gross proceeds of the offering, before underwriting discounts and commissions and other offering expenses payable by Adagio, were approximately $355.8 million.
  • Collaboration with Scripps: Adagio entered into an exclusive research agreement with The Scripps Research Institute to identify broadly protective vaccine candidates for the prevention of influenza and beta coronaviruses.
  • Board of Directors Expanded with Industry Leaders to Support Future Growth: Adagio recently announced appointments of three industry veterans and area experts to its board of directors:
    • Tom Heyman, former president of the Johnson & Johnson Development Corporation (JJDC);
    • Anand Shah, M.D., former deputy commissioner for medical and scientific affairs at the U.S. Food and Drug Administration (FDA); and
    • Michael S. Wyzga, president of MSW Consulting, Inc. and former CFO of Genzyme

Second Quarter 2021 Financial Results

  • As of June 30, 2021, Adagio had cash, cash equivalents and marketable securities of $392.5 million, which includes net proceeds from its Series C financing completed in April. Pro forma cash, cash equivalents and marketable securities as of June 30, 2021 is $719.6 million after giving effect to our initial public offering which closed on August 10, 2021.
  • Research & development expenses including in-process research and development for the second quarter of 2021 were $37.6 million.
  • Selling, general & administrative expenses for the second quarter of 2021 were $7.1 million.
  • Net Loss for the second quarter was $44.7 million, or $0.18 per share.

About ADG20
ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses, is being developed for the prevention and treatment of COVID-19, the disease caused by SARS-CoV-2. ADG20 was designed and engineered to possess high potency and broad neutralization against SARS-CoV-2 and additional clade 1 sarbecoviruses, by targeting a highly conserved epitope in the receptor binding domain. ADG20 displays potent neutralizing activity against the original SARS-CoV-2 strain as well as all known variants of concern. ADG20 has the potential to impact viral replication and subsequent disease through multiple mechanisms of action, including direct blocking of viral entry into the host cell (neutralization) and elimination of infected host cells through Fc-mediated innate immune effector activity. ADG20 is administered by a single intramuscular injection, and was engineered to have a long half-life, with a goal of providing both rapid and durable protection. Adagio is advancing ADG20 through multiple clinical trials on a global basis.

About Adagio Therapeutics

Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch. For more information, please visit www.adagiotx.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, the timing, progress and results of our preclinical studies and clinical trials of ADG20, including the timing of our planned IND submissions, initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs; our ability to obtain and maintain regulatory approvals for, our product candidates; our ability to identify patients with the diseases treated by our product candidates and to enroll these patients in our clinical trials; our manufacturing capabilities and strategy; and our ability to successfully commercialize our product candidates. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation, those risks described under the heading “Risk Factors” in Adagio’s prospectus filed with the Securities and Exchange Commission (“SEC”) on August 6, 2021 and in Adagio’s future reports to be filed with the SEC, including Adagio’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021. Such risks may be amplified by the impacts of the COVID-19 pandemic. Forward-looking statements contained in this press release are made as of this date, and Adagio undertakes no duty to update such information except as required under applicable law.

Contacts:

Media Contact:
Dan Budwick, 1AB
[email protected]

Investor Contact:
Monique Allaire, THRUST Strategic Communications
[email protected]

ADAGIO THERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

(In thousands, except share and per share amounts)

June 30,
2021		 December 31,
2020
Assets
Current assets:
Cash and cash equivalents(1) $ 392,509 $ 114,988
Prepaid expenses and other current assets 3,550 2,394
Total current assets 396,059 117,382
Deferred offering costs 1,933 —
Total assets $ 397,992 $ 117,382
Liabilities, Convertible Preferred Stock and Stockholders’ Deficit
Current liabilities:
Accounts payable $ 10,716 $ 8,153
Accrued expenses 27,181 4,919
Total current liabilities 37,897 13,072
Early-exercise liability 8 11
Total liabilities 37,905 13,083
Commitments and contingencies
Convertible preferred stock (Series A, B and C) $0.0001 par value; 16,944,484 shares authorized, issued and outstanding at June 30, 2021; 12,647,934 shares authorized, issued and outstanding at December 31, 2020; aggregate liquidation preference of $505,399 and $169,900 at June 30, 2021 and December 31, 2020, respectively 504,711 169,548
Stockholders’ deficit:
Common stock, $0.0001 par value; 150,000,000 shares authorized at June 30, 2021 and December 31, 2020; 5,599,240 shares issued and outstanding at June 30, 2021; 28,193,240 shares issued and 5,593,240 shares outstanding at December 31, 2020 1 1
Treasury stock, at cost; 0 shares and 22,600,000 shares at June 30, 2021 and December 31, 2020, respectively — (85 )
Additional paid-in capital 4,067 154
Accumulated deficit (148,692 ) (65,319 )
Total stockholders’ deficit (144,624 ) (65,249 )
Total liabilities, convertible preferred stock and stockholders’ deficit $ 397,992 $ 117,382

(1)     Pro forma cash, cash equivalents and marketable securities as of June 30, 2021 is $719.6 million after giving effect to our issuance and sale of 20,930,000 shares of our common stock in our initial public offering at the price of $17.00 per share after deducting underwriting discounts, commissions and estimated offering costs which closed on August 10, 2021.

ADAGIO THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)

(In thousands, except share and per share amounts)

Three Months
Ended
June 30,		 Six Months
Ended
June 30,		 Period from
June 3, 2020
(Inception) to
June 30,
2021 2021 2020 (3)
Operating expenses:
Research and development(1) $ 35,067 $ 69,204 $ 48
Acquired in-process research and development(2) 2,500 3,500 —
Selling, general and administrative 7,124 10,695 50
Total operating expenses 44,691 83,399 98
Loss from operations (44,691 ) (83,399 ) (98 )
Other income (expense):
Interest income 23 32 —
Other expense (5 ) (6 ) —
Total other income (expense), net 18 26 —
Net loss and comprehensive loss $ (44,673 ) $ (83,373 ) $ (98 )
Net loss per share attributable to common stockholders, basic and
diluted		 $ (0.18 ) $ (0.66 ) $ —
Weighted-average common shares outstanding, basic and diluted 249,769 125,574 21,250,000

(1)   Includes related-party amounts of $247 for the three months ended June 30, 2021, $435 for the six months ended June 30, 2021 and $0 for the period from June 3, 2020 (inception) to June 30, 2020.
(2)   Includes related-party amounts of $2,500 for the three months ended June 30, 2021, $3,500 for the six months ended June 30, 2021 and $0 for the period from June 3, 2020 (inception) to June 30, 2020.
(3)   The results for the period from June 3, 2020 (inception) to June 30, 2020 are the same for the three and six months ended June 30, 2020.

Posted on

FDA Clears First Technology to Distinguish between Bacterial and Viral Infections Using the Body’s Immune Response – The MeMed BV® Test and MeMed Key® Platform

FDA Clears First Technology to Distinguish between Bacterial and Viral Infections Using the Body’s Immune Response – The MeMed BV® Test and MeMed Key® Platform

  • MeMed BV is a first-of-its kind test that decodes the immune response to accurately distinguish between bacterial or viral infections within minutes
  • MeMed Key is a pioneering platform that enables rapid and sensitive measurements of multiple proteins at the point-of-need
  • The MeMed technology suite enables better informed antibiotic treatment decisions, an essential tool in the fight against the global threat of resistant bacteria

HAIFA, Israel, Boston, MA; September 20th, 2021 – MeMed, a leader in the emerging field of advanced host-response technologies, today announces that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for use of the MeMed BV® test on the point-of-need platform MeMed Key® to help healthcare providers distinguish between bacterial and viral infections. The technology has been cleared for both children and adults.

Bacterial and viral infections are often clinically indistinguishable, leading to the prescription of antibiotics for the treatment of viral infections, for which they are ineffective. Antibiotic misuse drives the emergence of antimicrobial resistance (AMR), one of the biggest healthcare challenges of our time.
The novelty of MeMed’s technology is that it decodes the body’s immune response to infection, the ‘host response’, rather than focusing on detecting the presence of a microbe. This allows robust diagnosis when the infection site is inaccessible or unknown, even when the pathogen is undetectable using conventional tests, or when the cause of infection are emerging new pathogens. It enables better informed antibiotic treatment decisions, an essential tool in the fight against resistant bacteria.

“For those of us who care for acutely ill children, we have been waiting decades for accurate, rapid diagnostics to confidently guide the care of moderately ill children without a clear focus of infection or recognizable viral illness. This novel test offers promise to help differentiate those children with self-limited viral illness from those with possible bacterial infection, thereby supporting the judicious use of antibiotics,” said Rich Bachur, MD, Professor of Pediatrics and Emergency Medicine, Harvard Medical School, and Chief, Division of Emergency Medicine, Boston Children’s Hospital.

“It has been a decade long journey to reach this point from concept to impacting patient lives,” said Dr. Eran Eden, MeMed’s co-founder and CEO. “This FDA clearance is a breakthrough moment in the field of advanced host-response and could not have been achieved without the dedication of the MeMed team, our clinical partners in the US and around the globe, and the support of the US Department of Defense and EU Commission.”

Sergey Motov, MD, Professor of Emergency Medicine, Maimonides Medical Center, New York, said: “Host-response technologies are a new frontier in the management of patients with infectious diseases, with great potential to improve patient outcomes. Every day, I see adults with a complicated medical history presenting to the emergency room with a suspected respiratory tract infection. A technology like MeMed BV can significantly aid in their management.”

“We are now using MeMed BV in my department routinely to aid in determining whether a child with fever has a bacterial or viral infection. For example, we recently had a complicated case of a young child with fever but without a clear source. MeMed BV helped in early identification of a severe bacterial infection, that would otherwise be masked by viral PCR detection, lead to a change in the course of treatment, and made a big difference in the patient’s outcome,” said Dr Adi Klein, Director of the Pediatric Division, Hillel Yaffe Medical Center and Head of the Israeli Clinical Pediatric Society. “Introducing MeMed’s technology has had a significant impact on our medical practice, enabling us to be better stewards of antibiotics and improving patient outcomes.”

FDA clearance was based on a multi-center blinded clinical validation study enrolling over 1,000 children and adults and addresses goals laid out in the US National Action Plan for Combating Antibiotic Resistant Bacteria. The test provides highly accurate results with Area Under the Curve of 90% and 97% (primary and secondary endpoints). MeMed has established its US base in Boston and is ramping up commercial activities to ensure broad availability of its products across the US.

About MeMed
Our mission is to translate the immune system’s complex signals into simple insights that transform the way diseases are diagnosed and treated, profoundly benefiting patients and society. To learn more about MeMed and our solutions, please visit http://www.me-med.com

About MeMed BV®
MeMed BV® is a first-of-its-kind immune-based protein signature test, developed and validated over the course of decade-long collaborations with leading academic and commercial partners. It provides physicians with an indispensable tool to help distinguish between bacterial and viral infections across multiple pathogens, even if the infection site is inaccessible or unknown. MeMed BV® measures and computationally integrates the levels of three immune system proteins: TRAIL, IP-10 and CRP. When run on the MeMed Key® platform, MeMed BV® provides a result within 15 minutes. MeMed BV® has been independently validated on thousands of patients and the results have been published in leading peer-reviewed journals (including Pediatrics, The Lancet ID,  PLOS One, BMJ Peds and European Journal of Clinical Microbiology & Infectious Diseases). The MeMed BV® test has received a CE Mark in Europe and AMAR clearance from the Israeli Ministry of Health.

About MeMed Key®
MeMed Key® is a pioneering technology platform, enabling highly sensitive measurements of multiple proteins, within minutes, at the point of need. It opens the way to quantification of a vast array of human proteins in healthy and disease states, where and when it actually matters. The MeMed Key® development program has been partially funded by the US Department of Defense and the EU Commission. MeMed Key® has received a CE Mark in Europe and AMAR clearance from the Israeli Ministry of Health.

MeMed Contacts:
Adee Mor, VP Marketing, MeMed
[email protected]
Kfir Emmer, CFO, MeMed
[email protected]

Media relations contact:
Consilium Strategic Communications [email protected]

Please click here to see the full release in Hebrew

Posted on

17th CISMEF Successfully Held with Focus on Sharing Opportunities and Benefits for SMEs worldwide

GUANGZHOU, China, Sept. 20, 2021 /Xinhua-AsiaNet/– The 17th China International Small and Medium Enterprises Fair (CISMEF) is held from September 16th to 19th in Guangzhou, the capital of south China’s Guangdong province. The Fair has attracted enterprises from more than 30 countries and regions to participate. It provides a perfect platform and creates new opportunities for SMEs home and abroad to boost their cooperation and development.

With robotic arms, automatic guided vehicles, the various products are a feast for the eyes.

Approximately 1000 enterprises, which are leaders in either special technologies, refined products and techniques, unique goods or services, or innovation in technology or production modes, have exhibited in CISMEF. They mainly focus on the industrial fields of smart manufacturing and artificial intelligence, equipment manufacturing, electronic information, bio-medicine, and food and agricultural products.

Apart from many dazzling exhibits, all kinds of business promotion opportunities and exchange activities are also attractions. CISMEF have arranged a series of activities targeted at exhibiting industrial fields, including 12 supply and demand docking activities, 4 thematic activities, 3 cross-border business matchmaking activities and 6 promotion activities for exhibitors abroad, in the hope of providing exhibitors and purchasers with more accurate and effective services.

It will be the first time for Kimsun Trade Co.LTD from Guangzhou participates in the CISMEF. Kimsun specializes in the electrostatic powder coating area, providing their customers with intelligent automatic coating schemes and services. Shu Gan, the Research and Development Director of Kimsun, indicated, “CISMEF provides an excellent platform for enterprises of special technologies like us. On the one hand, we have chances to promote our products and brands. On the other hand, it enables us to learn more about unique technologies from other areas, then absorbs and applies them into our area, offering customers better solutions.”

Display, transaction, exchange, cooperation. CISMEF has been working as an essential platform tailored for SMEs around the world. It provides information and business opportunities for enterprises to look for corporations between suppliers and buyers, and technical exchanges. Meanwhile, the Fair also strongly signals China’s promotion of communication and corporation between SMEs home and abroad, and proposes multilateral trade.

The International Cooperation Summit for SMEs, coupling with the fair, officially announced a considerable procurement plan for SMEs globally, valued at 826.3 billion yuan. A series of seminars have been arranged, including a ministerial-level roundtable centering on SME policies, to share experiences on how to effectively solve SMEs’ difficulties.

For many exhibitors, this superb international event of SMEs will accelerate their integration into global value chains and achieve mutual benefit and common prosperity. Guangdong Jaten Robot&Automation Co. Ltd debuts their new product of Automated Guided Vehicles in the Fair. Wang Meikui, the Deputy General Manager of the company, thinks that CISMEF provides a good chance for them to promote the product. “We would like to let more people get to know our product, and it’s very important,” she said.

Source: CISMEF

Posted on

IHC Upholds Legitimacy of Competition Act 2010 and CCP

The Islamabad High Court (IHC) has upheld the constitutionality of the Competition Act, 2010 and the Competition Commission of Pakistan (CCP).

The decision was announced in the court by Honourable Justice Babar Sattar in WP 4942/2010 titled ‘Islamabad Feeds and others vs Federation of Pakistan and others’.

On the constitutionality of the competition law, the court has held that the Parliament is the competent legislature to promulgate laws to regulate trade, commerce and intercourse across provinces and within any part of Pakistan under Article 151 of the Constitution.

Since the Competition Act, 2010 is a law that regulates the individual right to engage in trade and business in the interest of competition in order to provide for free trade, commerce and intercourse throughout Pakistan, the Parliament is competent to promulgate such laws. The Federation of Pakistan has the legislative competence to promulgate the Competition Act, 2010 and consequently the Competition Act, 2010 is intra vires the constitution.

This order of IHC adds on to the unanimous view of a three-member Lahore High Court (LHR) bench that has already declared, through its decision in WP 9518/2009 titled ‘LPGAP vs Federation of Pakistan, the Competition Act, 2010 as within the legislative competence of the Parliament. As a result, there remains no doubt about the constitutionality of the Competition Act, 2010.

This is a welcome outcome of an otherwise protracted constitutional litigation imposed on the Federation of Pakistan and CCP since the latter’s inception in 2007 by various business undertakings that were facing action under the law for anti-competitive behavior.

Source: Pro Pakistani

Posted on

FIA Jails CEO Elahi Group of Companies and Former Private Bank Officers for ‘Embezzlement’

The Federal Investigation Agency (FIA) has jailed Danish Elahi, Chief Executive Officer (CEO) Elahi Group of Companies, along with a few former employees of BankIslami Pakistan Limited, as a first information report (FIR) was registered against them for alleged embezzlement, involving irregularities and suspicious transactions discovered in their accounts.

Reports suggest that the evidence of misappropriation of financial assets against the accused has already been proven, and their remand was approved by a magistrate on a later date.

The Elahi Group is also an alleged defaulter of the bank, owing well over Rs. 1.4 billion in debt and related payments. In this regard, sources said, FIA was conducting a separate inquiry against defaulters and it was subject to further investigation upon retrieval of more evidence in the near future.

The Elahi Group of Companies has been involved in the supply chain business segment for procurement of raw materials for different manufacturing purposes, like production of transformers, inventory management, and storage and logistics of huge volume.

With the underlined embezzlement case likely to add up to the hardships in the company’s mounting struggles, many will wonder how the leadership behind the Elahi Group managed to fool regulators for so long with unverified holdings and off-the-books accounting practices.

Source: Pro Pakistani

Posted on

The Long Term Effects of Pakistan’s Education Crisis During the Pandemic [Opinion]

Just when schools and colleges in Pakistan reopened and life seemed to be returning to normalcy, the lockdown was extended, putting education at a greater risk than ever before.

Pakistan was one of the first countries that announced the closure of educational institutes to mitigate the spread of the coronavirus, and is still subject to repeated temporary reopening and closings.

An analysis of a study by a large-scale education systems research program, called RISE, suggests that if the 14-week closure of schools after the earthquake in 2005 was detrimental for student learning, this 18-month pandemic-induced closure is likely to have long-lasting effects on Pakistan’s human capital.

The shortcomings faced by remote learning as a result of digital inequalities and technological inabilities have created a huge gap in learning among students. Not only are they unable to learn new concepts and skills but are at the risk of forgetting what they learned earlier.

Additionally, the constant postponing and foregoing of examinations has raised serious concerns about the inability to assess the standards of learning and student achievement. This lack of assessment will harm students’ current level of learning and adoptions of skills and will affect their participation in future remedial policies to recover the losses in learning.

Geven and Hassan’s World Bank report on learning losses in Pakistan due to pandemic-induced school closures showed that Pakistani children who have already accumulated only 5.1 years of learning due to low-quality schooling systems might eventually only accumulate between 4.8 and 4.3 years by the end of the closure of the schools. However, it is important to note that the detection of these losses can take longer than expected, and the consequences may even be worse than anticipated.

Students Engage to Disengage

Earlier this year, students staged massive protests across Sindh and Punjab following the Ministry of Education’s announcement that examinations will be conducted in-person and on-campus. Even though the call for the canceling or postponing of examinations originated from the genuine concern of being unprepared due to inadequate remote learning facilities and poor internet connectivity, it was also an example of students disengaging with the system of educational assessment that has been set in place for years. They refused to take such examinations and requested to be promoted in compensation for the hindrances in their educational experiences.

While the students who are struggling to maintain their academic standards may be empathized with, it must be noted that many students do not fully comprehend the consequences of the cancellation of examinations. The circulation of social media memes and jokes about not wanting to go to school and hoping for them to remain closed are adequate proof of this.

It is crucial for students to be kept engaged and made fully aware of the repercussions of the closure of schools on their learning and skills development so that they may participate responsibly in the future remedial strategies of the educational institutions to compensate for this huge learning gap.

Long Term Impact on Skills: Are Students Industry-ready?

Recent studies have focused primarily on the short-term economic losses caused by the closure of colleges and universities across the world but little has been done to assess the long-term issues affecting both the students as the economies.

The World Bank’s Human Development Project revealed that children in Pakistan can achieve only 39 percent of their full potential, given the current educational and health opportunities. However, with both their health and education in jeopardy during the pandemic, it is certain that students will continue to suffer from a loss of knowledge and skills development that will prevent them from gaining footholds in the job market. Reductions in overall incomes and huge lost earnings by the global economy are already being predicted by international organisations, and must not be ignored.

The suspension of assessments and certifications, the unavailability of adequate educational platforms, and a huge fall in student motivation have disrupted the flow of growth and skill development among young people. Pakistan’s human capital resources that are already limited in quantity and quality are at the greatest risk of further deterioration.

While recent college graduates are facing unemployment or even underemployment due to limited vacancies in the job market, current school students are bound to face the consequences of this educational crisis in the coming years. However, their reasons for unemployment may not be the lack of job openings but the lack of skills and training needed to be able to fit into various industries.

If necessary measures to mitigate these long-term effects are not taken into account now, it might become impossible to control the imminent damage in the future.

Road to Recovery

It is impossible to truly capture the scale of the impact of the closure of schools on human capital in the upcoming years, and suggesting a concrete set of recovery measures that is guaranteed to mitigate the losses is also not feasible. However, based on past and current experiences, there are certain steps that can be taken to facilitate the process of recovery:

• Schools and colleges must be prepared to employ various methods of assessing students’ progress and learning abilities to create accelerated programs once they reopen.

• Rigorous training of teachers and staff must be conducted to equip them with skills and resources to help students recover the academic losses.

• Students must be taught and encouraged to maintain efficient learning habits to easily catch up with their studies when their remedial classes begin.

• Various means of including extracurricular activities and playtime for students must also be considered because social isolation and restrictions in physical activities have affected students’ mental health and prevent many from performing well.

• EdTech companies and online learning platforms should offer innovative learning resources to complement student growth.

• The government must allocate a reasonable budget to expand digital connectivity for students and support teaching and learning resources for schools.

It is, therefore, harmful to assume that reopening schools will eliminate the ongoing educational crisis. The effects of this crisis may take time to appear but the need to prepare to fight them is urgent.

Source: Pro Pakistani

Posted on

Covid-19: 40 more deaths, 2167 positive cases reported in country

Forty more deaths due to Coronavirus infection and 2,167 positive cases have been reported in the country.

According to the National Command and Operation Centre statistics, 51,348 tests were conducted yesterday while positivity ratio remained 4.22 percent.

Death toll due to the pandemic has now reached 27, 246.

Source: Radio Pakistan